Dr. Hsiu-Jung Lo, Investigator

Slides:

Advertisements

Similar presentations

List of the “bullet points” in the first FP7 calls for proposals

Advertisements

European Framework Programme for Business FP7 UK Technology Strategy Board Driving Innovation FP7UK Opportunities in FP 7 The Health research theme Biomed.

EU support for Health Research: from FP6 to FP7

What Do Toxicologists Do?

Health Departments and Healthcare-Associated Infection Prevention Research: A New Land of Opportunity? Matthew Wise, MPH, PhD Epidemiologist, Office of.

Biomedical research methods. What are biomedical research methods? An integrated approach using chemical, mathematical and computer simulations, in vitro.

Title of Presentation 1 EU-ASEAN S&T cooperation to jointly tackle societal challenges Opportunities for future EU-ASEAN collaborations.

European Health Forum Gastein, Bad Hofgastein, Austria, September 2002 Towards the Sixth Framework Programme Parallel Forum V 26 September 2002 Public.

SMEsgoHealth&Match2BioSME International Training&Workshop - September 13, 2007, Riga Health Theme in FP7 Dr. Uldis Berkis NCP Latvia Research areas in.

Overview of current ANCS activities in relation with IMI Ioana Ispas Advisor for Bioethics, Genomics and Health ANCS.

Chapter 13. The Impact of Genomics on Antimicrobial Drug Discovery and Toxicology CBBL - Young-sik Sohn-

Where to focus? Horizon 2020 'Health, demographic change and wellbeing' Open Info Day -Horizon 2020 'Health, demographic change and wellbeing' Brussels,

Annual prostate cancer symposium February 23, 2013 The Kimmel Cancer Center, Philadelphia, PA 2nd “ Novel Therapeutic Strategies for Prostate Cancer ”

New Treatments. New drug treatments Chronotherapy Lung cancer vaccine Summary.

1 EU-funded health research activities against TB: FP6 actions and perspectives toward FP7 DG Research - European Commission 22 MARCH 2007.

Clinical trials in Framework programme 7 (FP7) EU Judita Kinkorová 2. Národní konference o doporučených postupech, Olomouc 13. listopadu 2010.

Strategy and Policy Cohesion: “The One Health Agenda: will it deliver” Elizabeth J. Phillips, MD, FRCPC,FRACP, FACTM Professor & Director, Centre for Clinical.

Seventh Framework Programme Theme 1 - Health Ph D.Olguta Iordache Health - NCP.

Pollution and Human Health

The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.

IMMUNOHISTOCHEMICAL EXPRESSION OF MELK IN BREAST CANCER Manieli C*, Saccani S*, Lai ML*, Pilloni L*, Coni PP*, Senes G*, Faa G*, Van den Oord JJ°. *I Cattedra.

ESI workshop Stochastic Effects in Microbial Infection The National e-Science Centre Edinburgh September 28-29, 2010.

DENS 521 Clinical Dental Therapeutics 1 st Lecture By Abdelkader Ashour, Ph.D. Phone:

HORIZON 2020 SC1-Health, demographic change and wellbeing challenge Марина Николовска Министерство за образование и наука

UNDERSTANDING BIOTERRORISM: Tara O’Toole, MD, MPH The United States Conference of Mayors Mayors Emergency, Safety & Security Summit October 24, 2001.

Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.

R&D Blueprint : platform technologies to improve control of severe infectious diseases R&D Blueprint : platform technologies to improve control of severe.

Session VII WEIGHING IN ON MICROBIOLOGICAL ADI: EXPERIENCES AND PERSPECTIVES Introduction October 26, 2012.

Specialties and your career. Starting work in a lab When you apply for your first job in a laboratory it will be in a specific discipline: haematology.

‘‘EU-EaP STI Cooperation in Addressing Health Research and Innovation’’ Policy Stakeholders Conference, Budapest, May 2016 Report of the Panel ‘‘Challenges.

RESEARCH & INNOVATION SHOWCASE Dr Trish Murray Senior Lecturer in Stem Cell/Developmental Biology, ITM Senior scientist in the UK Regenerative Medicine.

PRESENTAZIONE DEL WORK PROGRAMME 2013 HEALTH Gabriella Balestra BIOLAB - Dipartimento di Elettronica e Telecomunicazioni.

Medical and Health research in Norway – in brief Director Mari K. Nes 22 June 2006.

1 NANO AMPLIFIED THERAPY INFN-Milano, INFN-Torino, INFN-Pisa, INFN- Roma3, CNR-Pisa, University of Torino - Biotechnology Department.

ROLE OF THE INSTITUTIONAL BIOSAFETY COMMITTEE

Nanomedicine Research at OU

Parasites have clocks iMM-Lisboa Should FCT fund discovery research,

FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health

Chapter Twenty: The Environment and Human Health

Assist. Prof Sinziana Istrate , MD, PhD University Emergency Hospital Bucharest- Neuro Ophthalmology department University of Medicine and Pharmacy Carol.

71 ViroLab – A virtual laboratory for decision support in viral diseases treatment ViroLab is sponsored by the European Union (contract number )

EU funding opportunities

What we all need to know about the powers that be!

Fighting resistant bacteria and Global pandemics

Antibody Drug Conjugates Services Antibody-drug conjugates Antibody-drug conjugates (ADCs) are a very important class of highly potent drugs designed as.

Gene Editing Tools and Methods

From Bench to Clinical Applications: Money Talks

ACEPRD FIVE YEAR WORK PLAN, ( )

A new antivirulence approach against pathogenic bacteria

Emerging Projects Day in One Health Final program

European & Developing Countries Clinical Trials Partnership (EDCTP)

Basics of Immunotherapy Potential Therapeutic Targets.

Advancing the Treatment of IBD With Biologics

Impact of JPIAMR funded projects: Strategy development

Strategy and Policy Cohesion: “The One Health Agenda: will it deliver”

Unit 4 - Immunology and Public Health

Potential mechanisms of therapeutic synergy between epigenetic modulation and PD-1 pathway blockade. Potential mechanisms of therapeutic synergy between.

InfoDays 2012 Environment Calls 17 June

Pollution and Human Health

Immunity to Infectious Diseases

Clonal dissemination of epidemic methicillin-resistant Staphylococcus aureus in Belgium and neighboring countries A. Deplano, W. Witte, W.J. Van Leeuwen,

Toxicological Analysis of Silver Nanoparticles and Colistin coated AgNp using Drosophila as a model organism” Dr. Ravish H Assistant Professor, Department.

Pima Medical Institute Online Education

FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health

Istituto Zooprofilattico Sperimentale dell’Abruzzo e Molise (IZSAM)

Management Board Meeting, 2-3 April 2019, Basel

NO BUG: Biobased mosquitoes repellent Personal protective equipment (PPE) L. Ciera*, V.A. Nierstrasz, L. Van Langenhove Department of Textiles,

Biomarkers as Endpoints

Prof. Jean-Marc Nabholtz, MD, MSc Chairman

Yeastern Biotech Co. Ltd.

Presentation transcript:

Dr. Hsiu-Jung Lo, Investigator Expertise: Infectious Diseases and Vaccinology Objectives of proposal: Develop vaccines and antimicrobial drugs for managing infectious diseases Partnership: Potential collaborator for 2.3.1 Anti-microbial drug resistance: Dr. Remko van Leeuwen, CEO at Madam Therapeutics, Amsterdam, Netherlands Specific topics : 1.3 Suitability, safety, efficacy of therapies 1.4 Innovative therapeutic approaches and interventions. 2.3.1 Anti-microbial drug resistance 2.3.3 Potentially new and re-emerging epidemics 2.3.4 Neglected infectious diseases

Dr. Pinpin Lin, Investigator Expertise, the objectives of proposal: Toxicology; Safety evaluation for nanoparticles and mechanistic studies for environmental chemicals-induced lung arcinogenesis. Partnership: Invited by Prof. Jean-Pierre Locquet, Solid State Physics and Magnetism Section, Katholieke Universiteit Leuven, Leuven, Belgium for the application of FP7-NMP- 2012-SMALL-6. Specific topics : Health.2013.1.3-1: Modelling toxic responses in case studies for predictive human safety assessment. FP7- HEALTH-2013-INNOVATION-1

Dr. Ko-Jiunn Liu, Associated Investigator Expertise: Tumour Immunology, Tumor and surrounding cell interaction Objective of proposal: Cell and antibody-based immunotherapy Partnership: Plan to collaborate with Prof. Gerold Schuler, University Hospital Erlangen, Erlangen, Germany Specific topics : Topic 2.4.1, Cell and antibody-based immunotherpy